Home » Gert Caspritz, Stephane Berghmans

Gert Caspritz, Stephane Berghmans

Mar 07, 2008
Premium
EpiCept this week announced that Gert Caspritz has resigned from the company's board of directors, effective March 6.
 
Caspritz, a general partner of TVM Capital, has been a member of the board since 1999 and served as EpiCept's chairman from July 2002 until December 2004.
 
 
Znomics has named Stephane Berghmans as director of drug discovery, effective March 10, the company announced this week.
 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Scan

More to Go Around

Congress approved a bill Friday that would increase the US National Institutes of Health's funding by $2 billion for fiscal year 2019.

Call for Ban

UK's Labour Party calls for a ban on non-invasive prenatal testing for determining sex, BBC News reports.

To Worry or Not?

Sarah Lawrence College's Laura Hercher warns in a New York Times op-ed that more people are going to need help figuring out what their consumer genetic testing results mean.

This Week in PLOS

In PLOS this week: intra-tumor heterogeneity patterns, genomic analysis of Thoroughbred horse origins, and more.

Sponsorships

Privacy Policy.  Terms & Conditions.  Copyright © 2018 GenomeWeb LLC.  All Rights Reserved.